Zhao-xiang Bian, MD, PhD; Hong-cai Shang, MD, PhD
Potential Conflicts of Interest: None disclosed.
Bian Z, Shang H. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Ann Intern Med. 2011;154:290-291. doi: 10.7326/0003-4819-154-4-201102150-00016
Download citation file:
Published: Ann Intern Med. 2011;154(4):290-291.
TO THE EDITOR:
The CONSORT (Consolidated Standards of Reporting Trials) 2010 statement (1) no longer advocates reporting the success rate of blinding in trials. We believe that this decision is unwise and will seriously undermine the quality of trials. The success of blinding relates directly to the quality of a trial and directly affects the outcome of interventions.
The importance of blinding is well known, and blinding helps to achieve quality assurance in trials. However, quality assurance does not rely on the setting but on the successful implementation of the trial protocol. The success rate of blinding is not only a factor by which to evaluate the effectiveness of blinding but is also an index to judge whether allocation concealment has been well conducted. If blinding and allocation concealment are considered critical factors for the quality of a trial, using them as criteria in assessing the success or quality of a trial is logical. Therefore, we totally agree with inclusion of the success rate of blinding in the previous version (2).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only